Olivier Favre-Bulle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Olivier Favre-Bulle has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Gilles Avenard
Acticor Biotech SAS, Hôpital Bichat - Inserm U1148, 46 rue Henri Huchard, F75018 Paris, France
2 shared publicationsKristell Lebozec
Acticor Biotech SAS, Hôpital Bichat - Inserm U1148, 46 rue Henri Huchard, F75018 Paris, France
2 shared publications- Philippe Billiald
Laboratory for Vascular Translational Science, UMR_S1148 INSERM, Université Paris Cité, Hôpital Bichat, Paris, France
2 shared publications Martine Jandrot-Perrus
Acticor Biotech SAS, Hôpital Bichat - Inserm U1148, 46 rue Henri Huchard, F75018 Paris, France; Inserm-University Paris Diderot UMR S1148, Hôpital Bichat, 46 rue Henri Huchard, F75018 Paris, France
1 shared publication- Martine Jandrot-Perrus
INSERM, U698, Hôpital Bichat, Paris, France
1 shared publication
Latest Publications
- Open Access
- 5 June 2017
- Published by Taylor & Francis in mAbs
- Vol. 9 (6) , 945-958
Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks
Glycoprotein VI is a platelet-specific collagen receptor critical for in vivo formation of arterial thrombosis. It is also considered as an attractive target for the development of anti-thrombotic drugs because blocking glycoprotein (GP)VI inhibits platelet aggregation without inducing detrimental effects on physiologic hemostasis. Here, we present data on the identification, in vitro and ex vivo pharmacology of a humanized Fab fragment designated as ACT017. ACT017 was selected out of 15 humanized variants based upon structural and functional properties. It was produced under GMP-like conditions followed by detailed physico-chemical analysis and functional characterization indicating high antigen-binding specificity and affinity. In addition, we demonstrate, in a dose-escalation study, that ACT017 has a high capacity to specifically inhibit collagen-induced platelet aggregation ex vivo after injection to the macaque without inducing thrombocytopenia, GPVI depletion or bleeding side effects as is the case for conventional anti-platelets. Therefore, ACT017 is a promising therapeutic candidate for the development of a new generation of safe and efficient anti-thrombotic drugs.
- 5 June 2017
- Published by Taylor & Francis in mAbs
- Vol. 9 (6) , 945-958
Open AccessDesign, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks
Glycoprotein VI is a platelet-specific collagen receptor critical for in vivo formation of arterial thrombosis. It is also considered as an attractive target for the development of anti-thrombotic drugs because blocking glycoprotein (GP)VI inhibits platelet aggregation without inducing detrimental effects on physiologic hemostasis. Here, we present data on the identification, in vitro and ex vivo pharmacology of a humanized Fab fragment designated as ACT017. ACT017 was selected out of 15 humanized variants based upon structural and functional properties. It was produced under GMP-like conditions followed by detailed physico-chemical analysis and functional characterization indicating high antigen-binding specificity and affinity. In addition, we demonstrate, in a dose-escalation study, that ACT017 has a high capacity to specifically inhibit collagen-induced platelet aggregation ex vivo after injection to the macaque without inducing thrombocytopenia, GPVI depletion or bleeding side effects as is the case for conventional anti-platelets. Therefore, ACT017 is a promising therapeutic candidate for the development of a new generation of safe and efficient anti-thrombotic drugs.